Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.
Sandhiya SelvarajanAnnuja AnandaradjeSanthosh ShivabasappaDeepthy Melepurakkal SadanandanN Sreekumaran NairMelvin GeorgePublished in: British journal of clinical pharmacology (2022)
In comparison to standard of care, dexamethasone was found to increase clinical recovery and lower mortality; remdesivir was significantly associated with a lower risk of mortality as compared to tocilizumab and higher clinical recovery and shorter time to clinical improvement as compared to hydroxychloroquine and tocilizumab; remdesivir followed by tocilizumab were found to have lesser occurrence of serious adverse events in patients with moderate to severe COVID-19.
Keyphrases
- rheumatoid arthritis
- coronavirus disease
- sars cov
- juvenile idiopathic arthritis
- cardiovascular events
- palliative care
- rheumatoid arthritis patients
- risk assessment
- low dose
- risk factors
- physical activity
- quality improvement
- cardiovascular disease
- early onset
- high dose
- pain management
- coronary artery disease
- health insurance
- drug induced
- affordable care act